Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow

Key Points

• Clear Eyes supply constraints remain Prestige’s biggest near-term challenge. The company expects fiscal 2027 organic growth of 1% to 3%, with the outcome dependent largely on improving availability; broader product restoration is expected to take years.
• Prestige is targeting at least $270 million in annual free cash flow, gross margins of roughly 57% and continued low-to-mid-30% EBITDA margins. Following acquisitions that lifted leverage above four times, management plans to prioritize debt reduction.
• Recent acquisitions of Breathe Right and LaCorium, along with growth in gastrointestinal brands such as Dramamine and Fleet, support Prestige’s longer-term outlook of about 10% revenue growth and 8% earnings-per-share growth over three years.

Prestige Consumer Healthcare NYSE: PBH said its strategy centers on investing in established over-the-counter brands, maintaining a high-margin operating model and using free cash flow for debt reduction, acquisitions and other shareholder-value initiatives.

Speaking at a fireside chat, Chief Financial Officer and Chief Operating Officer Chris Sacco described Prestige as a marketer and steward of brands in niche, needs-based categories. He said the company targets consumers who rely on familiar products when addressing health needs and uses consumer insights to expand category participation and encourage repeat usage.

Sacco said Prestige expects gross margin of roughly 57% during the year and has historically maintained EBITDA margins in the low-to-mid-30% range. The company’s free-cash-flow guidance is $270 million or more for the year, he said.

Clear Eyes Supply Remains Key Variable

Prestige’s largest near-term challenge has been supply constraints for its Clear Eyes eye-care brand, Sacco said. Fiscal 2026 revenue declined about 4.3%, with Clear Eyes supply limitations representing the primary restraint on organic growth, while the rest of the portfolio performed well, according to management.

“As fast as we can make it, we can ship it,” Sacco said, emphasizing that the constraint has been on the supply side rather than consumer or retailer demand.

For fiscal 2027, Prestige has guided to organic growth of 1% to 3%. Sacco said the extent of improvement in Clear Eyes supply will be the largest determinant of whether results land toward the high or low end of that range.

The company acquired Pillar5 Eyecare, a contract manufacturer, in December to support capacity and remediation efforts at its sterile eye-care facility. Sacco said heightened U.S. Food and Drug Administration enforcement activity has affected the sterile eye-care industry broadly. Prestige has replaced consultants at the Pillar5 site with permanent employees who have sterile eye-care experience, he said.

Vice President of Investor Relations, Treasury and Business Development Phil Terpolilli said Clear Eyes currently is focused on its two core stock-keeping units, Max Red and Base Red, rather than the seven or eight products historically available on shelves. He said availability remains sporadic in stores and that Prestige expects increased supply in the second half of the fiscal year. Restoring additional products and full distribution is expected to be a multiyear process.

Volume, Innovation and Channel Shifts

Sacco said Prestige’s organic growth is driven primarily by volume rather than pricing. The company generally pursues pricing through innovation, developing improved propositions that are intended to be margin-accretive to individual brands.

Terpolilli said consumers have generally continued to purchase trusted brands despite a pressured consumer environment, with no meaningful shift to private-label products observed across most of Prestige’s categories. However, shoppers are moving from higher-priced retail channels such as CVS and Walgreens toward value-oriented outlets including Walmart, dollar stores and Amazon, he said.

Prestige manages product distribution and retailer relationships so that shifts between channels do not dilute margins, Terpolilli said. E-commerce, which represented less than 1% of revenue when Sacco and Terpolilli joined the company in 2017, now accounts for a high-single-digit percentage of sales and has continued to grow at a double-digit pace, he added.

Management said e-commerce sales are primarily generated through Amazon and Walmart, and the company is seeking to maintain comparable profitability across online and brick-and-mortar channels.

GI Brands Benefit From Multiple Tailwinds

Prestige cited growth across its gastrointestinal portfolio, including Dramamine, Fleet, Gaviscon and Hydralyte. Terpolilli said use of GLP-1 drugs has created a tailwind for Dramamine and Fleet because nausea and constipation are the first- and second-most common side effects associated with those treatments.

The company has sought to support those brands through marketing and innovation. Recent launches include a Fleet mini enema kit designed to be more approachable for consumers unfamiliar with enemas or suppositories, as well as Compound W NitroFreeze, a higher-efficacy wart-treatment product.

Prestige generally aims to introduce three to five new products annually across its portfolio, Terpolilli said. The company’s innovation strategy focuses on extensions close to its existing products rather than developing new drugs.

Acquisitions, Margins and Capital Allocation

Management discussed two recent acquisitions: Breathe Right and Australia-based LaCorium Health. Breathe Right, acquired in June as the company’s largest acquisition to date, represents roughly $200 million in sales, according to Terpolilli. Prestige paid just over $1 billion for the portfolio.

Terpolilli said Breathe Right has about 80% market share in brick-and-mortar retail and is sold in approximately 20 countries. LaCorium, meanwhile, adds therapeutic skin-care products to Prestige’s Australian Care Pharmaceuticals platform and has grown at a double-digit annual rate over the past decade, he said.

Prestige finished the prior year with gross margin just below 56%. Management said the company’s updated gross-margin outlook of just over 57% is entirely attributable to the acquisitions, which are modestly accretive to gross margin. Any margin expansion is generally reinvested in marketing to support sales growth, Terpolilli said.

The acquisitions increased leverage from about 2.5 times to just above four times. Prestige plans to prioritize debt reduction through the end of the fiscal year and expects to reduce leverage by roughly two-thirds of a turn annually if free cash flow is directed entirely toward debt repayment.

Looking ahead, management reiterated a three-year outlook calling for approximately 10% total revenue growth, including 2% to 3% organic growth, and earnings-per-share growth of about 8%. The company expects to generate roughly $900 million in free cash flow over the next three years.

About Prestige Consumer Healthcare (NYSE:PBH)

Prestige Consumer Healthcare Inc NYSE: PBH develops, markets and distributes over-the-counter health care products and household consumer products. Its portfolio includes branded treatments for eye care, gastrointestinal health, women's health, oral care, respiratory conditions, pain relief and skin care, along with products for lice treatment and motion sickness.

The company's brands include Clear Eyes, Dramamine, Monistat, Summer's Eve, Compound W, Chloraseptic, Luden's, BC, Goody's, Nix and Hydralyte, among others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.